Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1978 Jul;6(1):81–86. doi: 10.1111/j.1365-2125.1978.tb01686.x

Comparison of digoxin and medigoxin in normal subjects.

R P Hayward, H Greenwood, J Hamer
PMCID: PMC1429382  PMID: 666950

Abstract

1 The properties of a recently introduced digitalis glycoside, 4-beta-methyl digoxin (medigoxin) were compared to those of a standard digoxin preparation. Using a radioimmunoassay (RIA) technique, serial plasma levels were recorded for 8 h following a single oral dose in five fasting volunteer subjects, and urinary glycoside elimination was measured for 4 consecutive days after dosage by use of a modification of the RIA method. 2 It was found that this RIA was suitable for plasma level measurement of both digoxin and midigoxin by reference to appropriate standard curves. Comparison of the plasma level profiles of these two drugs showed that medigoxin was very rapidly absorbed with peak levels occurring within 15--30 min, while digoxin produced peak levels after 45--75 min. The area under the plasma level-time curve produced by medigoxin was also consistently greater than that produced by digoxin, even though the medigoxin dose used was smaller. Quantitative comparison of these areas after adjustment to compensate for differing doses showed that medigoxin is considerably more biologically available than digoxin under study conditions (ratio 1.6 +/- 0.25:1), and comparison of quantitative urinary elimination suggested that medigoxin is eliminated in the urine to a lesser extent than digoxin and therefore it undergoes more metabolism and/or hepato-biliary elimination.

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Butler V. P., Jr Assays of digitalis in the blood. Prog Cardiovasc Dis. 1972 May;14(6):571–600. doi: 10.1016/0033-0620(72)90009-6. [DOI] [PubMed] [Google Scholar]
  2. Davidson C., Gibson D. Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. Br Heart J. 1973 Sep;35(9):970–976. doi: 10.1136/hrt.35.9.970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Doherty J. E. The clinical pharmacology of digitalis glycosides: a review. Am J Med Sci. 1968 Jun;255:382–414. doi: 10.1097/00000441-196806000-00006. [DOI] [PubMed] [Google Scholar]
  4. Greenwood H., Howard M., Landon J. A rapid, simple assay for digoxin. J Clin Pathol. 1974 Jun;27(6):490–494. doi: 10.1136/jcp.27.6.490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Greenwood H., Snedden W., Hayward R. P., Landon J. The measurement of urinary digoxin and dihydrodigoxin by radioimmunoassay and by mass spectroscopy. Clin Chim Acta. 1975 Jul 23;62(2):213–224. doi: 10.1016/0009-8981(75)90230-2. [DOI] [PubMed] [Google Scholar]
  6. Haass A., Lüllmann H., Peters T. Absorption rates of some cardiac glycosides and portal blood flow. Eur J Pharmacol. 1972 Sep;19(3):366–370. doi: 10.1016/0014-2999(72)90103-3. [DOI] [PubMed] [Google Scholar]
  7. Hayward R. P., Greenwood H., Hamer J. Proceedings: Problems associated with development of radioimunassay for urinary digoxin and its use in clinical assessment of biological availability. Br Heart J. 1975 May;37(5):560–560. [PubMed] [Google Scholar]
  8. Johnson B. F., Bye C. Maximal intestinal absorption of digoxin, and its relation to steady state plasma concentration. Br Heart J. 1975 Feb;37(2):203–208. doi: 10.1136/hrt.37.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. König E., Ohly A. Quantitative Eigenschaften eines neuen Herzglykosids. Med Klin. 1970 Feb 13;65(7):296–299. [PubMed] [Google Scholar]
  10. LEVY G., HOLLISTER L. E. INTER- AND INTRASUBJECT VARIATIONS IN DRUG ABSORPTION KINETICS. J Pharm Sci. 1964 Dec;53:1446–1452. doi: 10.1002/jps.2600531203. [DOI] [PubMed] [Google Scholar]
  11. Larbig D., Kochsiek K. Zur radioimmunchemischen Bestimmung von Digoxin und Digoxinderivaten. Dtsch Med Wochenschr. 1972 Sep 1;97(35):1310–1312. [PubMed] [Google Scholar]
  12. Lindenbaum J., Mellow M. H., Blackstone M. O., Butler V. P., Jr Variation in biologic availability of digoxin from four preparations. N Engl J Med. 1971 Dec 9;285(24):1344–1347. doi: 10.1056/NEJM197112092852403. [DOI] [PubMed] [Google Scholar]
  13. Marcus F. I., Ryan J. N., Stafford M. G. The reactivity of derivatives of digoxin and digitoxin as measured by the Na-K-atpase displacement assay and by radioimmunoassay. J Lab Clin Med. 1975 Apr;85(4):610–620. [PubMed] [Google Scholar]
  14. Rietbrock N., Abshagen U. Stoffwechsel und Pharmakokinetik der Lanataglykoside beim Menschen. Dtsch Med Wochenschr. 1973 Jan 19;98(3):117–122. doi: 10.1055/s-0028-1106760. [DOI] [PubMed] [Google Scholar]
  15. Shaw T. R., Howard M. R., Hamer J. Variation in the biological availability of digoxin. Lancet. 1972 Aug 12;2(7772):303–307. doi: 10.1016/s0140-6736(72)92908-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES